Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,084 recruiting studies in this area right now.
By phase
- Not applicable2,111
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California407
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,084 total
- NCT06529575Recruiting
How skin color affects pulse oximeter accuracy in children
This study checks if a child's skin color affects how well a pulse oximeter (a small clip on the finger that measures oxygen in the blood) works. It involves children having a heart catheterization, where doctors can directly measure oxygen levels, to see if the pulse oximeter gives the same reading.
New York, New YorkAges 4 weeks–18 years - NCT06529874Recruiting
Pain, balance, and strength in children with sickle cell
This study looks at how children (ages 9-14) with sickle cell anemia or who are healthy handle pressure, balance, and strength. It aims to understand pain and movement better to help improve care.
GizaAges 9–14 - NCT06530511RecruitingPhase 2
PRO trial for elderly, frail patients with a type of lymphoma
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
Nantong, JiangsuAges 60 years+ - NCT06530550RecruitingPhase 2
PI3K inhibitor for relapsed T/NK-cell lymphoma
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06530576RecruitingPhase 2
Thalidomide for symptomatic large granular lymphocytic leukemia
This trial tests the drug thalidomide for people with symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. It aims to see if thalidomide can help control the disease and improve symptoms like low blood counts or an enlarged spleen.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06531018RecruitingPhase 1/Phase 2
Eltrombopag for newly diagnosed ITP patients
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
DhakaAges 18–70 - NCT06532058RecruitingPhase 2
Study of a new drug for relapsed or hard-to-treat acute myeloid leukemia
This trial tests an experimental drug called QHRD107 combined with other medicines for people whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The goal is to see if the new combination is safe and helps control the leukemia.
Zhengzhou, HenanAges 18 years+ - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT06532552RecruitingPhase 2
Comparing four drug combinations for older or unfit AML patients
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Suzhou, JiangsuAges 18 years+ - NCT06532643RecruitingEarly Phase 1
CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Hefei, AnhuiAges 14–70 - NCT06532955Recruiting
Robot-assisted surgery for arm swelling after breast cancer
This trial tests a robotic surgical technique to reconnect tiny lymph vessels and reduce arm swelling (lymphedema) in women who had breast cancer treatment. It may help if your swelling is still in the early stages.
Maastricht, LimburgAges 18 years+ - NCT06532773RecruitingDurham, North CarolinaAges 18 years+
- NCT06533761RecruitingPhase 1
Eganelisib alone or with chemo for relapsed AML
This trial tests an experimental drug called eganelisib, either alone or with the chemotherapy drug cytarabine, for people with relapsed or refractory acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It aims to see if the drug is safe and can help control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
San Diego, CaliforniaAges 18 years+ - NCT06534021RecruitingPhase 1
Study of IASO-782 for autoimmune blood disorders
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
Wuhan, HubeiAges 18–65 - NCT06534463Recruiting
MZL patient registry study
This study is a registry that collects information on Chinese patients with marginal zone lymphoma. It helps doctors learn more about how MZL behaves and how it is treated.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT06534437RecruitingPhase 2
Study of MEN1703 for aggressive B-cell lymphoma
This trial tests a new drug called MEN1703, alone or with another drug (glofitamab), for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if it can help shrink tumors.
Le MansAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06535113Recruiting
Inflammation and treatment response in AML
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
Reggio Calabria, CalabriaAges 18 years+ - NCT06536010Recruiting
Testing a new combination therapy for AML
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Huai'an, JiangsuAges 18–75 - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06536959RecruitingPhase 2
VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT06537726Recruiting
Breath test for fungal infections in leukemia patients
This trial tests if a simple breath analysis can detect invasive fungal infections early in people with acute leukemia who are undergoing chemotherapy and have a low white blood cell count. Early detection could help start treatment sooner.
Zurich, Canton of ZurichAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,084 recruiting hematology studies from the U.S. registry right now, out of 7,742 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.